iMediSync

13/06/2025

Quick question for clinicians out there:

Do you ever feel like you’re guessing?

You try a treatment. You wait.
If it works, great. If not, you adjust and try again.

But what if we didn’t have to rely so much on trial and error?

We’ve been using EEG to get a clearer read on what’s actually going on in the brain — before deciding what to do next.
It takes 10 minutes and shows you patterns you can actually use.

No guesswork. No fishing. Just a map.

Curious — how are you currently making decisions around meds or brain-based treatments?

👇 Would love to hear how others are handling this.

👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar

12/06/2025

“It’s not all in your head.” Actually — it is in your head. And we can measure it.

Many patients struggling with anxiety, mood swings, or attention issues are used to being dismissed.
With EEG, we give them something different: data.

Our scans show when the brain is overactive, underactive, or out of sync. We can often correlate specific patterns — like elevated frontal theta or right-left asymmetry — with what patients describe in their daily lives.

It doesn’t replace the clinical interview. It supports it.
And in many cases, it helps people feel seen.

🧠 We use 19-channel dry EEG.
📊 qEEG maps, stress analysis, biomarkers, and more — all in under 10 minutes.

If you’re ready to validate, educate, and treat with confidence — we’d love to show you how it works.

👉 imedisyncamericas.com
👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar

11/06/2025

🧠 Using qEEG to Design Smarter Neurofeedback Protocols

When it comes to neurofeedback, individualized care makes all the difference.

Research continues to show that tailoring neurofeedback based on qEEG data leads to better outcomes — especially in conditions like ADHD. One multicenter study reported a 55% remission rate using qEEG-informed neurofeedback, compared to more generic approaches.

Instead of guessing, clinicians can use qEEG to pinpoint which areas of the brain are over- or under-regulated — then train specifically toward those patterns.

With iSyncWave and iSyncBrain, we make it easy to scan, analyze, and implement personalized NFB protocols in just minutes.

If you’re offering neurofeedback or considering it, EEG guidance isn’t optional anymore — it’s the standard.

👉 imedisyncamericas.com
👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar



References:

Arns, M., et al. (2020). EEG-based personalized neurofeedback improves outcomes in ADHD: a multicenter randomized controlled study. NeuroImage: Clinical, 28, 102399. https://pubmed.ncbi.nlm.nih.gov/32891892

Hammond, D.C. (2011). What is Neurofeedback? Journal of Neurotherapy, 15(4), 305-336. https://doi.org/10.1080/10874208.2011.623090

10/06/2025

Executive Function Starts in the Frontal Lobe — And We Can Measure It

Focus. Organization. Self-control. These aren’t abstract traits — they’re brain functions, and they live mostly in the frontal lobes.

With EEG, we can actually see when these systems are underactive. One common pattern?
👉 Low beta activity across frontal sites — often seen in people who struggle with decision-making, attention, and regulation.

At iMediSync, we use fast EEG scans to detect these patterns — then apply targeted PBM protocols to stimulate frontal activation and support better cognitive control.

It’s quick. Non-invasive. Repeatable. And easy to integrate into both clinical and wellness settings.

Interested in supporting executive function with brain-based tools?

👉 imedisyncamericas.com
👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar

09/06/2025

A 52-year-old woman with cognitive decline after a traumatic brain injury showed significant improvement in executive function following just four weeks of targeted near-infrared light therapy.

Her EEG showed elevated slow-wave activity in the temporal lobe — a common finding after TBI. After daily PBM treatments applied to the scalp, her results on the Stroop Color-Word Interference Test improved across the board:

Better word reading

Stronger response inhibition

Increased accuracy

This was part of a larger study that found medium to large effect sizes for PBM in subjects with TBI, outperforming the sham-treatment control group.

The takeaway: brain fog after trauma isn’t just something to live with. There are non-invasive tools — like PBM — that may help.

🧠 PBM settings used: 633 nm + 870 nm, bilateral application to temporal scalp
📊 Source: Naeser et al., Photomedicine and Laser Surgery, 2011

👉 imedisyncamericas.com
👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar

06/06/2025

🧠 Decreased Beta Activity: An EEG Biomarker in Traumatic Brain Injury

Traumatic Brain Injury (TBI) often leads to alterations in brainwave patterns, detectable through quantitative EEG (qEEG). One notable change is the reduction in beta frequency activity, which is associated with cognitive functions such as attention, alertness, and active thinking.

Clinical Insight:
A recent case involved a patient who experienced a traffic accident resulting in TBI. qEEG analysis revealed a significant decrease in beta activity, correlating with the patient's reported difficulties in concentration and executive functioning.

Research Findings:
Studies have demonstrated that TBI patients exhibit reduced beta power, particularly in frontal regions, reflecting impairments in cognitive processing and attention. For instance, research indicates that joint increases in theta power and decreases in beta power are observed in individuals with TBI, highlighting disruptions in neural networks responsible for executive functions.

Implications for Practice:

Objective Assessment: qEEG provides measurable data on beta activity, aiding in the diagnosis and understanding of TBI-related cognitive deficits.

Personalized Rehabilitation: Identifying specific EEG biomarkers allows for tailored neurorehabilitation strategies targeting the affected cognitive domains.

Monitoring Progress: Regular qEEG assessments can track changes in beta activity, informing the effectiveness of therapeutic interventions.

At iMediSync, our iSyncWave system offers advanced qEEG analysis, enabling clinicians to detect and monitor such biomarkers effectively.

👉 Learn more at: imedisyncamericas.com
👉 Schedule a demo: imedisyncamericas.com/demoschedule
👉 Join our masterclass: imedisyncamericas.com/implementation-webinar

05/06/2025

🧠 EEG Biomarkers in Mild Cognitive Impairment (MCI): Early Detection Through Brainwave Analysis

Mild Cognitive Impairment (MCI) represents a transitional stage between normal aging and dementia. Early detection is crucial for intervention and management. Quantitative EEG (qEEG) has emerged as a valuable tool in identifying neurophysiological changes associated with MCI.

Key EEG Findings in MCI:

Temporal Lobe Slowing: Increased theta and slow alpha power, particularly in the T5 region, have been observed in individuals with MCI. This slowing is indicative of disrupted neural activity in areas critical for memory and cognition.

Global Theta/Alpha Ratio Increase: A higher theta/alpha ratio across the brain correlates with cognitive decline and has been associated with progression from MCI to Alzheimer's disease.

Clinical Case Insight:

A recent qEEG assessment of a patient with MCI revealed:

Raw Data Inspection: Notable slowing in the T5 alpha region.

qEEG Findings: Elevated theta and slow alpha activity globally, with a positive MCI discriminant score.

These findings underscore the potential of qEEG in detecting subtle brainwave alterations before significant cognitive deficits manifest.

Implications for Practice:

Utilizing qEEG allows clinicians to:

Identify Early Biomarkers: Detect neural changes associated with MCI, facilitating timely intervention.

Monitor Disease Progression: Track changes in brain activity over time to assess the effectiveness of therapeutic strategies.

Personalize Treatment Plans: Tailor interventions based on individual neurophysiological profiles.

At iMediSync, our iSyncWave system provides clinicians with advanced qEEG analysis tools to support early detection and management of cognitive decline.

👉 Learn more at: imedisyncamericas.com
👉 Schedule a demo: imedisyncamericas.com/demoschedule
👉 Join our masterclass: imedisyncamericas.com/implementation-webinar

04/06/2025

🧠 Frontal Beta Spindles: A Distinct EEG Biomarker in ADHD

While elevated theta/beta ratios are commonly associated with ADHD, a subset of individuals exhibits a different EEG pattern: frontal beta spindles. These are bursts of high-frequency beta activity (typically 20–30 Hz) localized in the frontal regions, and they may indicate a unique neurophysiological profile.

Clinical Insight:
A case study of a 9-year-old boy with ADHD revealed prominent frontal beta spindles during EEG assessment. Notably, this pattern correlated with a lack of response to stimulant medications, suggesting that frontal beta spindles may serve as a biomarker for stimulant non-responsiveness.

Research Findings:
Studies have identified that approximately 20% of children with ADHD exhibit increased beta activity, particularly in the frontal regions. This subgroup often shows reduced responsiveness to stimulant treatments, highlighting the importance of EEG phenotyping in guiding therapeutic decisions.

Implications for Practice:

Personalized Treatment: Identifying frontal beta spindles can inform clinicians about potential stimulant non-responsiveness, prompting consideration of alternative therapies.

Enhanced Assessment: Incorporating EEG biomarkers into the diagnostic process allows for a more nuanced understanding of ADHD subtypes.

Targeted Interventions: Tailoring interventions based on EEG profiles can improve treatment efficacy and patient outcomes.

At iMediSync, our iSyncWave system facilitates the detection of such EEG biomarkers, enabling clinicians to personalize ADHD treatment strategies effectively.

👉 Learn more at: imedisyncamericas.com
👉 Schedule a demo: imedisyncamericas.com/demoschedule
👉 Join our masterclass: imedisyncamericas.com/implementation-webinar

03/06/2025

🧠 Can a Brain Scan Predict Antidepressant Success?

For many patients, finding the right antidepressant involves weeks of uncertainty. But emerging research suggests that EEG biomarkers can offer predictive insights into treatment outcomes.

A study published in Scientific Reports found that resting-state EEG patterns, particularly in the beta and alpha frequency bands, can forecast response to cognitive behavioral therapy in depression . Similarly, research in IEEE Transactions on Biomedical Engineering demonstrated that connectivity patterns in EEG signals could predict responses to the antidepressant sertraline .

At iMediSync, we're integrating these findings into our iSyncWave EEG system, enabling clinicians to:

Identify EEG biomarkers associated with treatment response

Tailor interventions based on individual brain activity patterns

Reduce the guesswork in prescribing antidepressants

By leveraging EEG data, we aim to personalize mental health treatment, improving outcomes and patient satisfaction.

👉 Learn more at: imedisyncamericas.com
👉 Schedule a demo: imedisyncamericas.com/demoschedule
👉 Join our masterclass: imedisyncamericas.com/implementation-webinar

02/06/2025

🎓 Ready to bring brain-based care into your clinic?

Join our live Thursday Masterclass at 4PM EST with Kody Newman and learn how to confidently implement EEG brain mapping and photobiomodulation (PBM) — from setup to protocol.

We’ll cover exactly what clinicians want to know:
🧠 How do I record clean EEGs?
📊 What do the reports actually mean?
💬 How do I explain this to patients and price it right?

Whether you’re new to EEG or looking to sharpen your skills, this session is packed with actionable insights.

📍 Sign up now: www.imedisyncamericas.com/implementation-webinar

02/06/2025

🧠✨ Welcome to EEG Biomarker Week!

This week, we’re diving into one of the most powerful applications of EEG: identifying brain-based biomarkers that can guide diagnosis, treatment selection, and clinical outcomes.

Each day, we’ll spotlight a different phenotype or brainwave pattern — and show how qEEG is reshaping how we understand conditions like:

ADHD

Depression

Cognitive decline

Emotional dysregulation

Medication response

From frontal beta spindles in stimulant non-responders to alpha asymmetry in mood disorders, we’ll be sharing research-backed insights, real-world case studies, and clinical tools that make precision mental health possible.

📊 The brain is full of data. EEG helps us read it.
Let’s decode the biomarkers together.

👉 imedisyncamericas.com
👉 imedisyncamericas.com/demoschedule
👉 imedisyncamericas.com/implementation-webinar

08/04/2024

https://www.imedisyncamericas.com/events

It's not too late to register for tomorrow's free EEG Grand Round session. April 9th, 9 Am - 11 Am Pacific.

Please take a look at our April 29th Event where psychiatrist Dr. Kourosh Edalati and renowned Jay Gunkelman with present.

Apr 9 Webinar, Sports, Grand rounds EEG-Guided Neurostimulation Grand Rounds Tuesday, 9 April 2024 9:00 am 11:00 am Google Calendar ICS Learn how to read qEEG reports to develop protocols for neurostimulation such as TMS or PBM.Tuesday, April 9th, 9 AM-11 AM PST View Event → Apr 29 Webinar, Sports...